Another P2X7 antagonist JNJ-54175446 is an orally bioavailable, central nervous system-penetrating; it is currently in Phase 2 clinical trial for the treatment of major depressive disorder (clinicaltrials.gov,NCT04116606). Here, P2RX7 is linked to major depressive disorder.